<DOC>
	<DOCNO>NCT01079195</DOCNO>
	<brief_summary>The aim post-marketing observational study ( PMOS ) provide data effectiveness tolerability Tarka patient high risk develop diabetes mellitus , prescribed physician community set accordance term local marketing authorization . The follow specific question address : - Effectiveness Tarka lower blood pressure hypertensive patient high risk develop diabetes , control single-drug therapy . - Tolerability Tarka assess withdrawal rate .</brief_summary>
	<brief_title>Effectiveness Tolerability TarkaÂ® Treatment Hypertensive Patients With High Risk Developing Diabetes Mellitus</brief_title>
	<detailed_description>This non-interventional , observational , open-label , multicountry , multicenter post-marketing study Tarka prescribe usual manner accordance term local market authorization regard dose , population indication . Patients high risk develop diabetes mellitus treat secondary care specialist ( internal medicine specialist , nephrologists , endocrinologist , etc . ) , whose hypertension control single-drug therapy include . The assignment patient treatment Tarka decide advance protocol fall within current practice . The prescription Tarka clearly separate decision include patient study . No additional procedure ( standard care ) shall apply patient . Each patient treat physician 's discretion . Dosing schedule accordance locally approve Summary Product Characteristics ( SmPC ) . Physicians provide study kit include protocol , Tarka 's locally approve SmPC , case report form patient enrol . The patient 's demographic data , height , weight waist circumference report Inclusion visit . The previous antihypertensive therapy note ( generic name drug total daily dose ) . All drug patient currently receive cardiovascular disease treatment record well . The patient follow via regular office visit determine physician . As study observational nature , patient follow-up interventional left judgment physician within 6-month period , defines survey patient . For indicative purpose , follow-up participant enable 3 patient visit period . For reason , likely visit define `` Inclusion visit '' treatment Tarka commence , `` Follow-up visit Month 3 `` `` Follow-up visit Month 6 '' , although date depend decision physician . As result , failure meet suggest date constitute breach protocol .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Adult patient either gender ( 18 year age ) , establish diagnosis essential hypertension ( systolic blood pressure/ diastolic blood pressure great 140/90 mmHg ) Patients control singledrug therapy decision make introduce Tarka Patients high risk develop diabetes mellitus ( define accord British Medical Society guideline ) least one follow symptom : Positive family history diabetes Obesity define Body Mass Index ( BMI ) great 30 kg/m^2 waist circumference great 102 cm ( male ) great 88 cm ( female ) Impaired fast plasma glucose ( FPG ) level 6.1 7.0 mmol/l ( 100126 mg/dl ) Patients know establish Type 2 diabetes mellitus The use Tarka contraindicate follow patient : Hypersensitive active substance inactive ingredient With cardiogenic shock With second third degree atrioventricular block except patient function artificial pacemaker With sick sinus syndrome except patient function artificial pacemaker With atrial fibrillation/flutter concomitant WolffParkinsonWhite syndrome With exist history angioedema associate administration angiotensinconverting enzyme ( ACE ) inhibitor With severe renal severe liver impairment In pregnant woman ( woman childbearing potential unwilling use contraception include ) Lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Effectiveness tolerability Tarka</keyword>
	<keyword>Hypertensive patient</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Observational study</keyword>
</DOC>